# Renagade Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renagade-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.renagadetx.com
- Total disclosed funding: $300M
- Latest round: Series A (May 23, 2023)
- Investors on record: 2

## About

Founded in 2021 and based in Massachusetts, US, Renagade Therapeutics, Inc. operates as a biotechnology platform that provides RNA medicines and research to cure diseases. As of 2023, Amit Munshi serves as the CEO of the company. In May 2023, Renagade Therapeutics, Inc. raised USD 300 million in series A funding from F2 Ventures and MPM Capital.

The company has developed a portfolio of RNA delivery methods, broadening the variety of disorders that can be addressed. The firm can deliver RNA, reprogram cells with increased expression, and partner with Orna Therapeutics to harness the RNA coding platform using its synergistic toolkit. Renagade offers expertise that includes a wide range of delivery technologies as well as a synergistic RNA toolbox that enables transport, coding, editing, and insertion. The company's technological capability allows it to possibly treat any disease, everywhere in the body, with RNA therapeutics.

The organization plans to use the May 2023 funding to further grow its RNA medicine research and development.

## Funding rounds

- Series A, May 23, 2023, $300M — MPM BioImpact, F2 Ventures

## Investors

- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- F2 Ventures (https://capitalatlas.ai/funds/f2-ventures) — Series A